MINOCIN

CorMedix is a commercial-stage biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, particularly in the acute care and hospital settings. The company's lead product, DefenCath, is an FDA-approved catheter lock solution designed to reduce the risk of catheter-related bloodstream infections in patients undergoing hemodialysis. In 2025, CorMedix significantly expanded its portfolio through the acquisition of Melinta Therapeutics, adding a suite of established anti-infective brands including Minocin for Injection, Rezzayo, Vabomere, Orbactiv, Kimyrsa, and Baxdela. This acquisition transformed CorMedix into a diversified specialty pharmaceutical leader with a strong presence in the infectious disease and critical care markets. The company continues to pursue lifecycle management and new indications for its marketed products, such as the expansion of Rezzayo for fungal infection prophylaxis.